Biomarin Pharmaceutical Inc. has announced its definitive agreement to acquire Amicus Therapeutics for $4.8 billion, marking a strategic move to strengthen its position as a leader in rare diseases. The acquisition will see Biomarin gaining access to two high-growth products, Galafold® (migalastat) for Fabry disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe disease, which collectively generated $599 million in revenue over the past four quarters.
Upon close, the transaction is expected to accelerate Biomarin's revenue growth and contribute to the company's financial outlook. Specifically, it is anticipated to be accretive to non-GAAP diluted earnings per share (EPS) in the first 12 months post-close and substantially accretive to non-GAAP diluted EPS beginning in 2027.
The acquisition is expected to diversify Biomarin’s commercial portfolio and expand its rare disease product offerings, providing opportunities to extend the reach of Galafold and Pombiliti + Opfolda across Biomarin’s global footprint.
Furthermore, the agreement is projected to increase Biomarin’s long-term compound annual growth rate (CAGR) through 2030 and beyond, with both Galafold and Pombiliti + Opfolda demonstrating high-growth potential. The acquisition is also expected to add revenue immediately after the transaction closes and create substantial shareholder value.
The deal, which is set to close in the second quarter of 2026, is subject to regulatory clearances, approval by Amicus' stockholders, and other customary closing conditions. Biomarin intends to finance the transaction through a combination of cash on hand and approximately $3.7 billion of non-convertible debt financing.
Today the company's shares have moved 19.39% to a price of $62.025. Check out the company's full 8-K submission here.
